Seasun Biomaterials has announced that it is about to release its second Covid-19 assay, the AQ-TOP COVID-19 Rapid Detection Kit. The announcement comes days after the company received a US Food and Drug Administration (FDA) Emergency Use Authorisation (EUA) for its U-TOP COVID-19 Real-Time Detection Kit.
The new kit enhances the speed, sensitivity and specificity of conventional molecular detection methods by combining isothermal amplification with a PNA detection probe. This has a highly accurate binding efficiency to the nucleic acid the kit targets. Specifically, it searches for the presence of the ORF1ab gene of the SARS-CoV-2 virus, with an endogenous control human RNase P gene.
Go deeper with GlobalData
The AQ-TOP kit received CE marking in March.
Seasun Biomaterials CEO Hee-Kyung Park said: “Currently, as Covid-19 is rapidly spreading globally and re-infection is reported frequently, we will produce more than 200,000 tests per day to deliver as fast as possible. As soon as the permit for the AQ-TOP COVID-19 Rapid Detection Kit has been completed, the kit will be provided globally and with the advantage that the rapid Covid-19 diagnosis will contribute to quick follow-up.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
